ADVERTISEMENT
ADVERTISEMENT

Caution: RNAi

Credit: © Biophoto Associates / Photo Researchers, Inc." /> Credit: © Biophoto Associates / Photo Researchers, Inc. The paper: D. Grimm et al., "Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways," Nature, 441:537-41, 2006. (Cited in 147 papers) The finding: While studying the potential of RNA interference (RNAi) to treat he

Bob Grant
Bob Grant

Bob Grant is Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.

View full profile.


Learn about our editorial policies.

<figcaption> Credit: © Biophoto Associates / Photo Researchers, Inc.</figcaption>
Credit: © Biophoto Associates / Photo Researchers, Inc.

The paper:

D. Grimm et al., "Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways," Nature, 441:537-41, 2006. (Cited in 147 papers)

The finding:

While studying the potential of RNA interference (RNAi) to treat hepatitis in knockout mice, Stanford geneticist Mark Kay and collaborators showed that long-term expression of high levels of short hairpin RNA (shRNA) could kill the animals. Kay says that an overexpression of shRNAs downregulated liver microRNAs, led to cell death, and caused liver failure.

The significance:

Kay's findings offered what City of Hope researcher, John Rossi, calls "a big yellow caution sign" to researchers studying RNAi-based therapies for potential use in humans. UCLA researcher Irvin Chen found similar results using RNAi to downregulate the CCR5 gene in primary human T cells in vitro. "These shRNAs were toxic to [T] cells over a period of...

The caveat:

Kay says that toxicity could be avoided by altering the RNAi treatment - his lab, for example, used a promoter that dialed down shRNA expression - while still effectively knocking down target genes. "We could get really good sustained knockdown if we just made modifications," Kay says.

The prospects:

Though this paper gave RNAi researchers pause, the approach has not been discarded. "I truly believe that this type of approach is going to be therapeutically useful for a lot of different things," says Kay, who continues to study RNAi treatments for hepatitis. "I think things should move forward in an expeditious but cautious manner."

Other tissues in which RNAi can be toxic:
Blood (Mol Therapy, 14:494-504, 2006)
Lung (Cancer Res, 67:2345-50, 2007)
Brain (Proc Natl Acad Sci, 105:5868-73, 2008)

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
ADVERTISEMENT